• 124
Added a post  to  , vaccines

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

COVID-19 survivors may have loss of brain tissue

Even mild cases of COVID-19 may lead to loss of brain tissue, according to findings from a long-term study involving 782 volunteers. As part of the ongoing UK Biobank study, participants underwent brain scans before the pandemic. For a before-and-after comparison, researchers invited 394 COVID-19 survivors to come back for follow-up scans as well as 388 healthy volunteers. Most of the COVID-19 survivors had had only mild-to-moderate symptoms, or no symptoms at all, while 15 had been hospitalized. Among the COVID-19 survivors, researchers saw "significant" loss of gray matter in regions of the brain related to smell and taste - the left parahippocampal gyrus, left orbitofrontal cortex and left insula. Some of the affected brain regions are also involved in the memory of experiences that evoke emotional reactions, the researchers noted in a report posted on medRxiv on Tuesday ahead of peer review. The changes were not seen in the group that had not been infected. The authors said more research is needed to determine whether COVID-19 survivors will have issues in the longer term with their ability to remember emotion-evoking events. They also do not yet know whether the loss of gray matter is a result of the virus spreading into the brain, or some other effect of the illness.

Full Article >>

Added a post  to  , vaccines

Drug makers are increasingly turning to monoclonal antibodies to protect the millions of people who can't use vaccines. But questions swirl about their cost and long-term viability.

As the COVID-19 vaccine rollout gathers pace, a population is at risk of being left behind: the millions of people around the globe who lack fully functional immune systems.

While the exact number of the immunocompromised worldwide is unknown, estimates suggest that about 10 million live in the U.S. alone, or around 3 percent of the national population. The number encompasses a diverse range of vulnerabilities, including rare genetic immune deficiencies, chronic illnesses that impair the immune system such as rheumatoid arthritis, and cancer and organ-transplant patients who must take immune-suppressing medications.

For them, vaccines will not be effective, because they are incapable of making their own antibodies to neutralize the SARS-CoV-2 virus. Instead, pharmaceutical companies around the world are racing to develop alternative treatments that bypass the immune system altogether.

The most common option is called monoclonal antibody treatments. These artificially generated antibodies mimic the body’s natural immune response by binding to key sites on the virus’ spike protein, preventing it entering cells and reproducing. Companies including AstraZeneca, Regeneron, and Eli Lilly are currently testing whether monoclonal antibodies can protect immunocompromised people from SARS-CoV-2.

Full Article >>